Why Pfizer Inc. (PFE) stock moved
Pfizer Inc. (PFE) shares rose 2.0% to $30.55 as of October 30, 2026, a modest gain from the prior close of $29.95. BestStocks flagged the session as a major change for PFE. The move is tied to company news. Below, we break down what changed for PFE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Pfizer's ELREXFIO met primary endpoint in Phase 3 multiple myeloma trial, outperforming standard regimens. Positive data strengthens ELREXFIO's commercial potential and supports label expansion in relapsed/refractory myeloma market.
What it means for Pfizer Inc. investors
For Pfizer Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Positive 2.0% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in PFE's fundamentals. Wall Street's consensus price target sits at $29.17, implying -4.5% downside from $30.55. BestStocks rates the overall signal quality low (44/100). With earnings roughly 4 days out, the next report is the most likely near-term test of the move.
PFE price reaction
PFE last traded at $30.55, up $0.60 (+2.00%) from the previous close of $29.95. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +1.9% over the same stretch, leaving PFE essentially in line with peers. Over the past month the stock has ranged between $27.41 and $30.55, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Pfizer Inc. (PFE)
The consensus analyst price target on Pfizer Inc. (PFE) is $29.17, 4.5% below the recent $30.55. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PFE line up.
The bullish case
- The Street's most bullish target is $33.00 (+8.0%).
- Positive 2.0% session move.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $29.17 sits 4.5% below the recent $30.55, so the average target sees limited room to run.
- The most bearish analyst target is $26.00 (-14.9%).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for PFE
Frequently asked questions about PFE
Why did Pfizer Inc. (PFE) stock move?
PFE rose 2.0% to $30.55. The move is associated with company news and looks like a sector-wide move.
How much did PFE stock rise?
PFE gained 2.00% ($0.60) versus the prior close of $29.95, last trading at $30.55 on 0.5× average volume.
When is Pfizer Inc.'s next earnings date?
PFE's next earnings report is estimated for 2026-11-03 — about 4 days away.
What is the analyst price target for PFE?
The consensus analyst price target for PFE is $29.17, about 4.5% below the current $30.55. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
Is the PFE move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +1.9% against PFE's +2.0%. PFE ranks top 4 of 7 peers.
How BestStocks tracks PFE
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for PFE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.